التفاصيل البيبلوغرافية
| العنوان: |
Differing effects on hip and nonspine fracture risk reduction among N-containing bisphosphonates: Review and meta-analysis |
| المؤلفون: |
Liberman, UA, Hochberg, MC, GEUSENS, Piet, Ross, PD |
| بيانات النشر: |
SPRINGER LONDON LTD |
| سنة النشر: |
2006 |
| المجموعة: |
Document Server@UHasselt (Universiteit Hasselt) |
| الوصف: |
Objectives: N-containing bisphosphonates reduce the risk of vertebral fractures (VFx): however, results have not shown consistent effects on hip and other nonspine fractures. Systematic reviews are useful to summarize effects that often vary among individual trials, and meta-analysis provides a more precise estimate when results are consistent across pooled trials.(1) Methods: We surveyed earlier systematic reviews and meta-analyses ogether with subsequent reports (2-4) of randomized, placebo-controlled trials with data on nonspine and/or hip fractures, and used meta-analysis where appropriate to test for heterogeneity and derive pooled estimates. Results: For risedronate (RIS) (n=12958 subjects in trials), the relative risk (RR) reduction was 27% for nonspine fracture (RR=0.73; 95% CI= 0.61, 0.87)1 and 26% for hip fracture (RR=0.74; 0.58, 0.94); there was no significant interaction of treatment and age >80 and there was no heterogeneity by dose (2.5 or 5 mg/day). For alendronate (ALN), heterogeneity existed; doses >10 mg/day were significantly more effective for reduction of nonspine and hip fracture. The RR reduction with ALN >10 mg (n=3723) was 49% for nonspine fractures (RR=0.51; 0.38, 0.69).1 The RR reduction for hip fracture was 55% (RR=0.45; 0.28, 0.71) when osteoporotic women in FIT (ALN 5 mg/day in years 1–2 then 10 mg/day for remainder of trial) were included (n=6804), and 55% (RR=0.45; 0.18, 1.13) for doses >10 mg/day (n=3723).1 One post-hoc analysis suggested an effect of ibandronate (IBN) on non-spine fractures in patients with severe osteoporosis, but the limited fracture data and differences in dosing precluded pooling studies for meta-analysis. No data are available on the effect of IBN on hip fracture. Consequently, there is no consistent evidence of hip or nonspine fracture risk reduction available for meta-analysis. No data are available on the effect of IBN on hip fracture. Consequently, there is no consistent evidence of hip or nonspine fracture risk reduction available for ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| تدمد: |
0937-941X |
| Relation: |
OSTEOPOROSIS INTERNATIONAL, 17. p. S222-S223; http://hdl.handle.net/1942/1964; S223; S222; 17; 000245980600294 |
| الاتاحة: |
http://hdl.handle.net/1942/1964 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| رقم الانضمام: |
edsbas.C68B8022 |
| قاعدة البيانات: |
BASE |